临床试验/NCT00581854

NCT00581854已完成2 期

Phase II Pilot Study of Hyper-CVAD Plus Rituximab for Previously Untreated Mantle Cell Lymphoma

University of Wisconsin, Madison2 个研究点分布在 1 个国家目标入组 22 人开始时间: 2000年6月最近更新: 2019年12月13日

适应症

试验速览

阶段: 2 期
状态: 已完成
发起方: University of Wisconsin, Madison
入组人数: 22
试验地点: 2
主要终点: Complete Response Rate to Induction Therapy

研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

rituximab and modified (hyperCVAD) administered every 28 days for 4-6 cycles followed by rituximab maintenance therapy consisting of four weekly doses every six months for two years

详细描述

rituximab and modified hyperfractionated cyclophosphamide, vincristine doxorubicin, dexamethasone (hyperCVAD) administered every 28 days for 4-6 cycles followed by rituximab maintenance therapy consisting of four weekly doses every six months for two years

研究设计

研究类型: Interventional
分配方式: Na
干预模型: Single Group
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Untreated mantle cell lymphoma

排除标准

•Pregnant or breast feeding

结局指标

主要结局

Complete Response Rate to Induction Therapy

时间窗: Median follow up of 37 months

Outcome is the % of subjects who achieved a Complete Response (CR) or Complete Response Unconfirmed (CRu) after induction therapy, following the Cheson et al criteria for standardized response criteria (1999).

次要结局

未报告次要终点

研究者

发起方

University of Wisconsin, Madison

申办方类型

Other

责任方

Sponsor

研究点 (2)

Loading locations...

相似试验

已完成

2 期

Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell LymphomaContiguous Stage II Mantle Cell LymphomaNoncontiguous Stage II Mantle Cell LymphomaStage I Mantle Cell LymphomaStage III Mantle Cell LymphomaStage IV Mantle Cell Lymphoma

NCT00433537National Cancer Institute (NCI)77

已完成

2 期

Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell LymphomaMantle Cell Lymphoma

NCT00581776University of Wisconsin, Madison30

招募中

2 期

Rituximab Plus Venetoclax in Front Line Marginal Zone LymphomaMarginal Zone LymphomaMZLLymphoma

NCT06510309Gottfried von Keudell, MD PhD33

已完成

2 期

Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/LymphomaBurkitt's LymphomaBurkitt'S-like Lymphoma

NCT00669877M.D. Anderson Cancer Center56

招募中

2 期

Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic LeukemiaB Acute Lymphoblastic LeukemiaB Lymphoblastic Lymphoma

NCT02877303M.D. Anderson Cancer Center80